Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

27.11 +1.29 (+4.98%)
Streaming Delayed Price Updated: 3:13 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,557,742
Open 26.35
Bid (Size) 27.10 (400)
Ask (Size) 27.11 (800)
Prev. Close 25.82
Today's Range 25.72 - 27.17
52wk Range 8.730 - 25.95
Shares Outstanding 692,072,184
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a... 
Via Finterra
Topics ETFs Economy Initial Public Offering

Performance

YTD
+23.7%
+23.7%
1 Month
+23.3%
+23.3%
3 Month
+28.0%
+28.0%
6 Month
+142.7%
+142.7%
1 Year
+151.2%
+151.2%

More News

Read More
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Via Chartmill
Why Did Roivant Sciences Stock Gain 9% Pre-Market Today? ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 10, 2025 ↗
Via Benzinga
News headline image
Earnings Preview For Roivant Sciences ↗
Via Benzinga
News headline image
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
From Pulmovant, Inc.
Via GlobeNewswire
News headline image
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
From Roivant Sciences
Via GlobeNewswire
News headline image
The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Signals Major Pipeline Momentum With Accelerated Timelines ↗
Via Benzinga
News headline image
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant (ROIV) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
Via Benzinga
News headline image
Looking Into Roivant Sciences Ltd's Recent Short Interest ↗
Via Benzinga
News headline image
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
6 Analysts Assess Roivant Sciences: What You Need To Know ↗
Via Benzinga
News headline image
Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17 ↗
Via Stocktwits
News headline image
Why Roivant Sciences Stock Is Soaring Today ↗
Via The Motley Fool
News headline image
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial ↗
Via Benzinga
News headline image
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗
Via Benzinga
News headline image
Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease ↗
Via Investor's Business Daily

Frequently Asked Questions

Is Roivant Sciences Ltd. - Common Shares publicly traded?
Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.
What exchange does Roivant Sciences Ltd. - Common Shares trade on?
Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?
The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market
What is the current price of Roivant Sciences Ltd. - Common Shares?
The current price of Roivant Sciences Ltd. - Common Shares is 27.11
When was Roivant Sciences Ltd. - Common Shares last traded?
The last trade of Roivant Sciences Ltd. - Common Shares was at 02/09/26 03:13 PM ET
What is the market capitalization of Roivant Sciences Ltd. - Common Shares?
The market capitalization of Roivant Sciences Ltd. - Common Shares is 18.76B
How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?
Roivant Sciences Ltd. - Common Shares has 19B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.